OUR SCIENCE

From discovery to personalized medicines

Stellate Therapeutics has generated a portfolio of characterized candidates using its microbiome-derived medicine platform, which spans discovery and screening to production and biomarker identification:

Big data discovery engine

Indication screening process

Proprietary chemical synthesis

Next-Gen biomarkers for personalized medicine

Genomic profiling to identify lead compounds

Candidates are assessed for their roles in human biology under steady-state and diseased conditions, moving from in silico assessment to in vitro indication screening

De-risk the drug development process

Benefits of using co-evolved molecules

In conventional drug development, it is not until late in the process of clinical trials that biology is tested in humans

By conducting human observation studies (including case-controlled and epidemiological studies) on patient samples during the preclinical phase, we obtain critical information early, de-risking the drug development process

What is the Gut-Brain Axis?

The gut-brain axis (GBA) is a bidirectional link between the central nervous system (CNS) and the enteric nervous system (ENS) of the body. The CNS constantly reacts to what happens in the intestinal tract including the activity of the bacteria that live there. For example, 95% of serotonin is produced in the gut and participates in the interactions between the brain and gut via the vagus nerve. Furthermore, researchers have just recently begun achieving significant progress in understanding the consequences of disrupting the GBA on CNS function including mechanisms related to neurodevelopmental, psychological and neurodegenerative brain diseases (such as Parkinson’s and Alzheimer’s Disease).

What is the Microbiome?

The gut microbiome is the sum total of microorganisms that colonize the digestive tract. It is populated by nearly 100 trillion bacteria and many other microorganisms – slightly more than the total number of cells in the human body. Interestingly, each person has a unique microbiota makeup, called a “signature”, determined by a number of genetic, dietary and environmental factors.

What is its Role?

The gut microbiome has many functions. It plays a barrier role shielding against pathogens and a defense role that is critical to stimulate and educate the host’s immune system from the very early post-natal period of life. It also plays a role in the host’s metabolism participating in food breakdown and processing in many ways:

  • It can digest certain foods (e.g., dietary fiber) that humans are not able to digest
  • It produces important molecules (e.g., short-chain fatty acids) when it breaks down fibers which have essential benefits such as anti-inflammatory properties
  • It facilitates absorption of dietary minerals (e.g., magnesium, iron and calcium)
  • It synthesizes essential vitamins (e.g., vitamin K and folate) as well as amino acids
  • It also acts on xenobiotics and drug metabolism

 

Furthermore, the gut microbiome displays a maintenance role as it preserves the intestinal mucosa which helps to digest and absorb dietary nutrients as well as prevent potentially harmful substances or bacteria from entering the blood stream. It is in constant 2-way symbiotic communication with various organs to maintain physiological homeostasis.

The Microbiome and Disease

As it happens, our lifestyle and diet have been leading to a significant loss of microbial diversity in our internal ecosystem – and, with it, of microbial functions. This loss of diversity along with the reduction or increase of some bacterial species in relation to others can disrupt the equilibrium of the microbiota and be linked to the development of diseases. This imbalance (known as dysbiosis) is associated with various intestinal pathologies (antibiotic-associated diarrhea, chronic inflammatory bowel diseases, irritable bowel syndrome, etc.) and non-intestinal pathologies (metabolic diseases, cardiovascular diseases, and auto-immune diseases).

From discovery to personalized medicines

Stellate Therapeutics has generated a portfolio of characterized candidates using its microbiome-derived medicine platform, which spans discovery and screening to production and biomarker identification:

Big data discovery engine

Indication screening process

Proprietary chemical synthesis

Next-Gen biomarkers for personalized medicine

Genomic profiling to identify lead compounds

Candidates are assessed for their roles in human biology under steady-state and diseased conditions, moving from in silico assessment to in vitro indication screening

De-risk the drug development process

Benefits of using co-evolved molecules
In conventional drug development, it is not until late in the process of clinical trials that biology is tested in humans.
By conducting human observation studies (including case-controlled and epidemiological studies) on patient samples during the preclinical phase, we obtain critical information early, de-risking the drug development process.

From discovery to personalized medicines

Stellate Therapeutics has generated a portfolio of characterized candidates using its microbiome-derived medicine platform, which spans discovery and screening to production and biomarker identification:

Big data discovery engine

Indication screening process

Proprietary chemical synthesis

Next-Gen biomarkers for personalized medicine

Genomic profiling to identify lead compounds

Candidates are assessed for their roles in human biology under steady-state and diseased conditions, moving from in silico assessment to in vitro indication screening

De-risk the drug development process

Benefits of using co-evolved molecules
In conventional drug development, it is not until late in the process of clinical trials that biology is tested in humans.
By conducting human observation studies (including case-controlled and epidemiological studies) on patient samples during the preclinical phase, we obtain critical information early, de-risking the drug development process.

From discovery to personalized medicines

Stellate Therapeutics has generated a portfolio of characterized candidates using its microbiome-derived medicine platform, which spans discovery and screening to production and biomarker identification:

Genomic profiling to identify lead compounds

De-risk the drug development process